2024 and beyond: addressing ongoing safety and toxicity challenges for the future of the I-O field

Immuno-Oncology Insights 2023; 4(7), 261-266

DOI: 10.18609/ioi.2023.036

Published: 25 October
Rakesh Dixit

On September 12, 2023 Roisin McGuigan, Editor, Immuno-Oncology Insights, spoke to Rakesh Dixit PhD, DABT Cofounder, President and CSO, Regio Biosciences, Bionavigen, LLC and ex-VP of AstraZeneca, about addressing the safety and toxicity hurdles in the I-O field today. As a key opinion leader in the oncology biologics and safety assessment space, Rakesh Dixit comments on the field’s attempts to achieve the holy grail of I-O: targeting tumor cells with greater accuracy to improve safety and efficacy. This article has been written based on that discussion.